WuXi Biologics.
Chinese pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 27
What's happening
Earlier this month
One to three months ago
-
A company aims to expand commercial reach into Latin America, with ANVISA certification validating manufacturing standards in Brazil.Some support4 reports
-
Baidu and WuXi Biologics showed strong performance on benchmarks but were impacted by a cautious outlook for the China market.Some support1 report
-
WuXi Biologics received EMA approval and successfully passed FDA GMP inspection.Some support2 reports
-
WuXi Biologics, based in Jiangsu, filed its company results with the Hong Kong stock exchange.Some support1 report
Gone quiet
No new reports in 90+ days-
WuXi Biologics facility passed FDA Pre-License Inspection.Some support3 reports
-
MSCI awarded AAA ESG rating to WuXi Biologics.Some support3 reports
-
WuXi Biologics maintains operational bases in China and leverages a global CRDMO network for client support.Well supported4 reports2 developments inside
-
WuXi Biologics facility passed GMP inspection with zero critical findings, leading to EMA support for EU marketing authorization.Well supported3 reports
-
DP15 achieved GMP release in April by leveraging the global CRDMO network capabilities.Some support1 report
-
Whitehawk Therapeutics, Inc. in-licensed assets from WuXi Biologics and participated in conferences in New York City on September 3, 2025.Some support3 reports
-
WuXi Biologics, a spin-out from WuXi AppTec, was incorporated in the Cayman Islands in 2017.Some support3 reports
No events began in the chosen period. Widen it, or reset.
What's reaching WuXi Biologics
Events traced to WuXi Biologics, step by step, newest firstAround WuXi Biologics this week
News at the entities that move WuXi Biologics most-
FDA StructuralThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves WuXi Biologics
-
Cayman Islands StructuralA company was identified as a Cayman Islands exempted company on November 6, 2026.Moves WuXi Biologics
-
European Medicines Agency StructuralMenarini Group and NewAmsterdam Pharma Company N.V. are collaborating on drug development, seeking marketing authorization in Europe through the EMA and EC process.Moves WuXi Biologics
-
GMP StructuralKlemm discussed funding for a City Park project, and GMP provided construction packages for the initiative.Moves WuXi Biologics
-
MSCI StructuralPrabowo Subianto sacked Listyo Sigit Prabowo and faces warnings regarding an MSCI downgrade.Moves WuXi Biologics
-
Hong Kong OperationalAu Kam San was sentenced in a Macao court, underscoring the political control of Macau and Hong Kong by China.Moves WuXi Biologics
Connections
The 17 strongest of 27, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA formally inspects and regulates WuXi Biologics' manufacturing facilities to ensure compliance.
-
Chris Chen Structural
Chris Chen serves as the Chief Executive Officer of WuXi Biologics.
-
Cayman Islands Structural
WuXi Biologics is formally incorporated in the Cayman Islands.
-
European Medicines Agency Structural
The European Medicines Agency regulates WuXi Biologics through facility inspections and enforcement of GMP standards.
-
WuXi AppTec Structural
WuXi Biologics was founded as a spin-out and operates as a subsidiary of WuXi AppTec.
-
GMP Structural
WuXi Biologics' facility must adhere to GMP standards for operational compliance.
-
MSCI Structural
MSCI applies its formal ESG rating model and inclusion criteria to evaluate and recognize WuXi Biologics' compliance and performance.
-
Europe Structural
WuXi Biologics' operations are subject to regulatory inspections and approvals by European agencies like the EMA.
Show all 17 connections
-
Hang Seng Indexes Company Mentioned together
The entities are co-mentioned as demonstrating excellence in ESG performance.
-
Baidu Mentioned together
Both Baidu and WuXi Biologics were noted as strong performers on a benchmark.
-
Suzhou Shared context
WuXi Biologics maintains a Biosafety Testing Center within the geographical boundaries of Suzhou.
-
Wuxi Shared context
The company is based in the location of Wuxi, providing its operational context.
-
Basel Shared context
Basel serves as the geographical context for the biopharmaceutical industry, hosting events relevant to WuXi Biologics' sector.
-
Latin America Shared context
WuXi Biologics plans to expand its commercial operations into the Latin American market.
-
Jiangsu Shared context
WuXi Biologics is based in the Jiangsu province.
-
Hong Kong Operational
WuXi Biologics utilizes the Hong Kong stock exchange for filing financial results.
-
Hebei Shared context
WuXi Biologics operates a facility within the geographical boundaries of Hebei Province.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
1 eventAugust 2026
1 eventShow 2 earlier months
July 2026
2 eventsJune 2026
6 events- A company aims to expand commercial reach into Latin America, with ANVISA certification validating manufacturing standards in Brazil.
- WuXi Biologics maintains operational bases in China and leverages a global CRDMO network for client support.
- WuXi Biologics facility passed GMP inspection with zero critical findings, leading to EMA support for EU marketing authorization.
- DP15 achieved GMP release in April by leveraging the global CRDMO network capabilities.
- Whitehawk Therapeutics, Inc. in-licensed assets from WuXi Biologics and participated in conferences in New York City on September 3, 2025.
- WuXi Biologics, a spin-out from WuXi AppTec, was incorporated in the Cayman Islands in 2017.